Alzheimer’s drug that slows early stages approved in Canada

Breakdown

• Leucanumab has been conditionally approved in Canada to slow early-stage Alzheimer's. 17s
• The drug targets amyloid plaques and must be given early, with effects seen after about 18 months. 45s
• Clinical reports show leucanumab slows memory loss by 27 percent but may cause brain swelling or bleeding. 1m 0s
• The drug requires ongoing scans for safety and is costly, raising questions about its value. 1m 9s
• Some health agencies, such as in the UK, have not approved leucanumab due to concerns over cost and monitoring. 1m 44s